Affordable Access

Access to the full text

Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial

Authors
  • Demaria, Sandra1, 2
  • Romano, Emanuela3
  • Brackstone, Muriel4
  • Formenti, Silvia C.1
  • 1 Department of Radiation Oncology, Weill Cornell Medicine, 1300 York Ave, Box 169, New York, NY, 10065, USA , New York (United States)
  • 2 Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Ave, Box 169, New York, NY, 10065, USA , New York (United States)
  • 3 INSERM U932, Institut Curie, 26 rue d’Ulm, Paris, 75005, France , Paris (France)
  • 4 Division of Surgical Oncology, London Regional Cancer Program, 790 Commissioners Road East, London, Ontario, N6A 4L6, Canada , London (Canada)
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Nov 21, 2019
Volume
7
Issue
1
Identifiers
DOI: 10.1186/s40425-019-0783-x
Source
Springer Nature
Keywords
License
Green

Abstract

Programmed cell death protein 1 (PD-1) blockade is only effective in a minority of patients, prompting the search for combinatorial therapies that increase responses. Identifying effective combinations requires lengthy testing and so far has shown few successes. To accelerate progress Voorwerk and colleagues (Nat Med. 25(6):920-8, 2019) used an adaptive trial design to compare 4 short-course therapies (radiotherapy, cyclophosphamide, cisplatin and doxorubicin) for their ability to improve the tumor immune microenvironment and enhance responses to subsequent PD-1 blockade in women with metastatic triple negative breast cancer, a disease with low response rate to PD-1 blockade. They reported the first phase of the trial that enrolled 12 to 17 patients per arm to “pick the winner” induction treatment. Higher objective response rates (ORR) compared to no induction were observed only in the arm containing doxorubicin, which proceeded to phase II. These results raise a number of questions about testing local versus systemic induction treatments and whether sequencing with PD-1 blockade is appropriate in light of evidence supporting concomitant treatment, at least for radiotherapy. Small imbalances in baseline characteristics can also influence results obtained with limited numbers of patients per arm. We hope that these considerations will help future adaptive, signal-finding combination immunotherapy studies.

Report this publication

Statistics

Seen <100 times